<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>PURPOSE: Previous studies have shown increased risks of <z:e sem="disease" ids="C0085183" disease_type="Neoplastic Process" abbrv="">second malignancies</z:e> after non-Hodgkin's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (NHL) and <z:hpo ids='HP_0005550'>chronic lymphocytic leukemia</z:hpo> (CLL); however, no earlier investigation has quantified differences in risk of new <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">malignancy</z:e> by <z:hpo ids='HP_0002665'>lymphoma</z:hpo> subtype </plain></SENT>
<SENT sid="1" pm="."><plain>PATIENTS AND METHODS: We evaluated <z:e sem="disease" ids="C0751623" disease_type="Neoplastic Process" abbrv="">second cancer</z:e> and <z:hpo ids='HP_0001909'>leukemia</z:hpo> risks among 43,145 1-year survivors of CLL/small lymphocytic <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">SLL</z:e>), diffuse large B-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCL</z:e>), or follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (FL) from 11 Surveillance, Epidemiology, and End Results (SEER) population-based registries during 1992 to 2006 </plain></SENT>
<SENT sid="2" pm="."><plain>RESULTS: Among patients without HIV/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AIDS</z:e>-related <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, <z:e sem="disease" ids="C0242379" disease_type="Neoplastic Process" abbrv="">lung cancer</z:e> risks were significantly elevated after <z:e sem="disease" ids="C1302547" disease_type="Neoplastic Process" abbrv="">CLL/SLL</z:e> and FL but not after <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCL</z:e> (standardized incidence ratio [SIR], <z:e sem="disease" ids="C1302547" disease_type="Neoplastic Process" abbrv="">CLL/SLL</z:e> = 1.42, FL = 1.28, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCL</z:e> = 1.00; Poisson regression P for difference among subtypes, P(Diff) = .001) </plain></SENT>
<SENT sid="3" pm="."><plain>A similar pattern was observed for risk of <z:hpo ids='HP_0012056'>cutaneous melanoma</z:hpo> (SIR: <z:e sem="disease" ids="C1302547" disease_type="Neoplastic Process" abbrv="">CLL/SLL</z:e> = 1.92, FL = 1.60, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCL</z:e> = 1.06; P(Diff) = .004) </plain></SENT>
<SENT sid="4" pm="."><plain><z:hpo ids='HP_0011009'>Acute</z:hpo> nonlymphocytic <z:hpo ids='HP_0001909'>leukemia</z:hpo> risks were significantly elevated after FL and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCL</z:e>, particularly among patients receiving initial chemotherapy, but not after <z:e sem="disease" ids="C1302547" disease_type="Neoplastic Process" abbrv="">CLL/SLL</z:e> (SIR: <z:e sem="disease" ids="C1302547" disease_type="Neoplastic Process" abbrv="">CLL/SLL</z:e> = 1.13, FL = 5.96, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCL</z:e> = 4.96; P(Diff) &lt; .001) </plain></SENT>
<SENT sid="5" pm="."><plain>Patients with HIV/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AIDS</z:e>-related <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (n = 932) were predominantly diagnosed with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCL</z:e> and had significantly and substantially elevated risks for second <z:e sem="disease" ids="C0153446" disease_type="Neoplastic Process" abbrv="">anal cancer</z:e> (SIR = 120.50) and <z:hpo ids='HP_0100726'>Kaposi's sarcoma</z:hpo> (SIR = 138.90) </plain></SENT>
<SENT sid="6" pm="."><plain>CONCLUSION: Our findings suggest that differing immunologic alterations, treatments (eg, <z:chebi fb="0" ids="22333">alkylating agent</z:chebi> chemotherapy), genetic susceptibilities, and other risk factors (eg, <z:mp ids='MP_0001799'>viral</z:mp> <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infections</z:e>, tobacco use) among <z:hpo ids='HP_0002665'>lymphoma</z:hpo> subtypes contribute to the patterns of <z:e sem="disease" ids="C0085183" disease_type="Neoplastic Process" abbrv="">second malignancy</z:e> risk </plain></SENT>
<SENT sid="7" pm="."><plain>Elucidating these patterns may provide etiologic clues to <z:hpo ids='HP_0002665'>lymphoma</z:hpo> as well as to the <z:e sem="disease" ids="C0085183" disease_type="Neoplastic Process" abbrv="">second malignancies</z:e> </plain></SENT>
</text></document>